# CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

> **NCT06479356** · PHASE2 · RECRUITING · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Relma-cel

## Key facts

- **NCT ID:** NCT06479356
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479356, "CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06479356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*